JP2016513665A - ラキニモドの経皮製剤 - Google Patents

ラキニモドの経皮製剤 Download PDF

Info

Publication number
JP2016513665A
JP2016513665A JP2016502251A JP2016502251A JP2016513665A JP 2016513665 A JP2016513665 A JP 2016513665A JP 2016502251 A JP2016502251 A JP 2016502251A JP 2016502251 A JP2016502251 A JP 2016502251A JP 2016513665 A JP2016513665 A JP 2016513665A
Authority
JP
Japan
Prior art keywords
laquinimod
transdermal patch
pharmaceutical composition
weight
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016502251A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016513665A5 (enExample
Inventor
ステファン、ラルフ
ミカ、ハンズ−ユールゲン
プリーズ、タンヤ
シェンク、ディルク
プロール、サビーネ
Original Assignee
テバ ファーマシューティカル インダストリーズ リミティド
テバ ファーマシューティカル インダストリーズ リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テバ ファーマシューティカル インダストリーズ リミティド, テバ ファーマシューティカル インダストリーズ リミティド filed Critical テバ ファーマシューティカル インダストリーズ リミティド
Publication of JP2016513665A publication Critical patent/JP2016513665A/ja
Publication of JP2016513665A5 publication Critical patent/JP2016513665A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2016502251A 2013-03-14 2014-03-13 ラキニモドの経皮製剤 Withdrawn JP2016513665A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361781585P 2013-03-14 2013-03-14
US61/781,585 2013-03-14
PCT/US2014/026807 WO2014152009A1 (en) 2013-03-14 2014-03-13 Transdermal formulations of laquinimod

Publications (2)

Publication Number Publication Date
JP2016513665A true JP2016513665A (ja) 2016-05-16
JP2016513665A5 JP2016513665A5 (enExample) 2017-05-18

Family

ID=50729775

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016502251A Withdrawn JP2016513665A (ja) 2013-03-14 2014-03-13 ラキニモドの経皮製剤

Country Status (8)

Country Link
US (1) US20160038435A1 (enExample)
EP (1) EP2968203A1 (enExample)
JP (1) JP2016513665A (enExample)
CA (1) CA2900977A1 (enExample)
HK (1) HK1220125A1 (enExample)
IL (1) IL240557A0 (enExample)
MX (1) MX2015010967A (enExample)
WO (1) WO2014152009A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106063787A (zh) 2012-02-03 2016-11-02 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
WO2015138887A1 (en) * 2014-03-14 2015-09-17 Teva Pharmaceutical Industries Ltd. Transmucosal delivery of laquinimod by oral patches
CN112656778A (zh) * 2020-12-28 2021-04-16 广东红珊瑚药业有限公司 一种压敏胶基质以及一种贴剂

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
RS53666B1 (sr) 2005-10-19 2015-04-30 Teva Pharmaceutical Industries Ltd Kristali lakvinimod natrijuma i proces za njihovo dobijanje
UA96449C2 (en) 2006-06-12 2011-11-10 Тева Фармасьютикл Индастриз, Лтд. Stable laquinimod preparations
SI2234485T1 (sl) 2007-12-20 2014-03-31 Teva Pharmaceutical Industries Ltd. Stabilni lakvinimodni pripravki
BRPI0913518A2 (pt) 2008-09-03 2016-07-26 Teva Pharma composto, composição farmacêutica, e, método de tratamento de um distúrbio mediado por função imune
WO2010147665A1 (en) 2009-06-19 2010-12-23 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with laquinimod
CA2769623A1 (en) 2009-07-30 2011-02-03 Teva Pharmaceutical Industries Ltd. Treatment of crohn's disease with laquinimod
HUE029983T2 (en) 2009-08-10 2017-04-28 Teva Pharma Treatment of BDNF-related diseases with laquinimod
DE102010026879A1 (de) * 2010-02-11 2011-08-11 AMW GmbH, 83627 Transdermales System mit Immunmodulator
CN102781240A (zh) 2010-03-03 2012-11-14 泰华制药工业有限公司 用拉喹莫德和甲氨蝶呤的组合治疗类风湿性关节炎
BR112012022064A2 (pt) 2010-03-03 2015-09-08 Teva Pharma tratamento de artrite lúpica usando laquinimod
BR112012021905A2 (pt) 2010-03-03 2015-09-29 Teva Pharma tratamento de nefrite lúpica usando laquinimod
US8252993B1 (en) 2010-05-25 2012-08-28 Pioneer Hi-Bred International, Inc. Inbred maize variety PH18FN
MX2013000333A (es) 2010-07-09 2013-02-26 Teva Pharma N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinoli na-3-carboxamida deuterada, sales y usos de la misma.
BR112013000607A2 (pt) 2010-07-09 2016-06-28 Teva Pharma 5-cloro-4-hidroxi-1-metil-2-oxo-n-fenil-1,2-di-hidroquinolina-3-carboxamida, os sais e suas utilizações
KR20130124518A (ko) 2010-12-07 2013-11-14 테바 파마슈티컬 인더스트리즈 리미티드 다발경화증 환자의 피로를 감소시키고, 기능 상태를 개선시키고, 삶의 질을 개선시키기 위한 라퀴니모드의 용도

Also Published As

Publication number Publication date
MX2015010967A (es) 2015-10-26
US20160038435A1 (en) 2016-02-11
WO2014152009A1 (en) 2014-09-25
HK1220125A1 (zh) 2017-04-28
CA2900977A1 (en) 2014-09-25
IL240557A0 (en) 2015-10-29
EP2968203A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
KR101734602B1 (ko) 도네페질 함유 경피 흡수형 제제
KR101444967B1 (ko) 활성 물질로서 부프레노르핀을 투여하기 위한 경피 치료 시스템
KR101725832B1 (ko) 경피 흡수형 제제
AU2011345574B2 (en) Percutaneous absorption preparation containing rivastigmine
DE112014002664T5 (de) Transdermales Verabreichungssystem
EP1651215A1 (de) Transdermales therapeutisches system mit dem wirkstoff pramipexol
TWI664265B (zh) 貼附劑
KR102771688B1 (ko) 바레니클린의 경피 투여를 위한 약학 제제
NZ301197A (en) Transdermal formulation of xanomeline for treating alzeheimers disease
JP2016513665A (ja) ラキニモドの経皮製剤
EP0727208B1 (en) Transdermal formulation of a compound having muscarinic activity
EP1589973B1 (en) Formulation and methods for the treatment of thrombocythemia
AU2012218255B2 (en) Transdermal delivery system containing galantamine or salts thereof
US5605701A (en) Transdermal formulation
PL175077B1 (pl) Przezskórny układ terapeutyczny do leczenia jaskry oraz sposób otrzymywania przezskórnego układu terapeutycznego do leczenia jaskry
WO2006080199A1 (ja) 貼付剤
US20120052112A1 (en) Risperidone-containing transdermal preparation and adhesive patch using same
JP7716111B2 (ja) 神経変性疾患の症状の緩和又は治療のための貼付剤
JP2004067539A (ja) 経皮投与用貼付剤
US20040197397A1 (en) Drug delivery system for treatment of urinary incontinence
KR102362912B1 (ko) 첩부제
JP2025502532A (ja) セレキシパグの経皮投与のための経皮治療システム
JP2016196426A (ja) フェンタニル含有貼付剤
KR20180035859A (ko) 경피 전달 시스템
HK1170938A (en) Transdermally absorbable donepezil-containing preparation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170323

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20170807